Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (1683)
All Articles published online
|
Publishing Process of This Article
|
Oct 28, 2024 (publication date) through Mar 7, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhang H, Dong X, Zhu L, Tang FS. Elafibranor: A promising treatment for alcoholic liver disease, metabolic-associated fatty liver disease, and cholestatic liver disease. World J Gastroenterol 2024; 30(40): 4393-4398 [PMID: 39494094 DOI: 10.3748/wjg.v30.i40.4393] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v30/i40/4393.htm |
| Number | Citing Articles |
| 1 |
Ana Paula Madariaga Traconis, Misael Uribe-Esquivel, Varenka Julieta Barbero Becerra. Exploring the Role of Peroxisome Proliferator-Activated Receptors and Endothelial Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease. Cells 2024; 13(24): 2055 doi: 10.3390/cells13242055
|
| 2 |
Samira Farhadi, Saeed Mohammadi, Abdulaziz Y AlKindi, Issa S Al-Amri. Therapeutic potential of elafibranor in alcohol-associated liver disease: Insights into macrophage modulation and fibrosis reduction. World Journal of Biological Chemistry 2025; 16(1): 104535 doi: 10.4331/wjbc.v16.i1.104535
|